Quantity of eligible people: CDEC talked about the uncertainty in the amount of patients with moderately serious to severe hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some clients who will be labeled as getting mild or moderate disorder can have a significant bleeding